Post

NETRIS Pharma begins subject dosing in solid tumour therapy trial

The trial will assess the biological and clinical activity of NP137 as an add-on therapy in solid tumours patients.

Intravacc enrols first subject in intranasal Covid-19 booster trial

The initial interim data from the trial is anticipated by the end of the first quarter of next year.

Friedreich’s ataxia: major trial readouts and regulatory events to watch in 2023

The FDA could approve the first treatment for Friedreich’s ataxia, and at least three other major trials have readouts expected by year end.

Autobahn begins dosing in Phase I major depressive disorder treatment trial

An oral TRβ agonist, ABX-002 had shown target engagement in areas of the brain linked to depression.

VIDA introduces updated platform for clinical trial imaging operations

The platform has been launched to accelerate the onboarding of clinical trial sites.